ArticleTherapeutics and clinical risk management2023

Lenvatinib Plus PD-1 Inhibitors versus Regorafenib in Patients with Advanced Hepatocellular Carcinoma After the Failure of Sorafenib: A Retrospective Study.

Yongkang Xu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.